Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Investor Presentation (December 2013)
18 slides from Ani Pharmaceuticals's investor presentation, Dec 11, 2013
Slide 1: A Specialty Pharmaceutical Company – Corporate Presentation December 2013
A Specialty Pharmaceutical Company NASDAQ: ANIP HIGH POTENCY DRUGS – NARCOTIC DRUGS – RX LIQUIDS AND TABLETS – CONTRACT MANUFACTURING Corporate Presentation December 2013
Slide 2: Cautionary Statement Concerning Forward-Looking Statements
2 Cautionary Statement Concerning Forward - Looking Statements This presentation and certain information incorporated herein by reference contain forward - looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about
Slide 3: ANI Mission Statement
3 3 ANI Mission Statement ANI Pharmaceuticals is an emerging specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. ANI’s mission is to market niche generic pharmaceuticals, focusing on opportunities in pain management (narcotics),
Slide 4: ANI Overview – Poised for Growth
4 ANI Overview – Poised for Growth ANI Today ▪ Core competencies: marketing and manufacturing ▪ Two manufacturing facilities: narcotics and potent compounds ▪ Experienced management team ▪ Existing business + potential future royalty stream – For the nine - month period ended Sept. 30, 2013 (1) : $1
Slide 5: ANI Recent History and Highlights
5 5 ANI Recent History and Highlights 2009 New executive management team: Art Przybyl, CEO and Charlotte Arnold, CFO 2010 New management expands ANI strategy to include ANI labeled Rx products 2011 ANI expands marketed Rx portfolio to seven products through internal development and acquisition 2013
Slide 6: Sales and Marketing / Financial Overview
6 6 Sales and Marketing / Financial Overview
Slide 7: ANI Historical Revenue Growth
7 $9 $17 $20 $20 $28.6 $0 $5 $10 $15 $20 $25 $30 2010 2011 2012 2013 2013E ANI Historical Revenue Growth 7 $s in millions +30% Year/Year growth 39% 42% 43% 34% C ost of sales as a percentage of net revenues, excluding depreciation and amortization 1 (1) Unaudited (1Q – 3Q) (Guidance)
Slide 8: ANI Current Rx Product Portfolio
8 ANI Current Rx Product Portfolio Market Generic Products Position Share (1) EE/MT Tablets #1 92% Fluvoxamine Tablets #1 54% HC Enema #1 85% Metoclopramide Solution #2 31% Opium Tincture #1 75% 8 Branded Products Cortenema TM Reglan Tablets TM (1) Based on Company estimates, and recent IMS and NSP
Slide 9: ANI Rx Portfolio Prescription Volumes
9 ANI Rx Portfolio Prescription Volumes 9 Source: IMS Health 0 5,000 10,000 15,000 20,000 25,000 30,000
Slide 10: ANI Contract Manufacturing and Royalties
10 ANI Contract Manufacturing and Royalties 10 Current Business ▪ $5.7 million in contract manufacturing and services revenues during the nine - month period ended Sept. 30, 2013 (1) ▪ Five customers – Eleven products and fourteen SKUs Future Opportunities ▪ Three customers in development – Three pr
Slide 11: ANI 3Q 2013 Financial Highlights
11 ANI 3Q 2013 Financial Highlights 11 4Q13 Guidance $9M+ in revenues representing 15% sequential growth source: 3Q13 press release ($ in millions) Three months ended September 2013 September 2012 Net Revenues $7.8 $5.0 Adjusted EBITDA $1.7 $0.3 Adjusted EPS $0.16 n/a Select Balance Sheet Data Septe
Slide 12: Product Development / Business Development Overview
12 12 Product Development / Business Development Overview
Slide 13: ANI Product Development Highlights
13 13 ANI Product Development Highlights 12 p roducts in development ▪ Five filed ANDAs ▪ Seven ANDAs in progress – Development partners: Ricon and Sofgen ▪ Total combined current market: $850 million (1) Therapeutic Category Filed In Development Market Size (1) ($ in millions) Oncolytics and Narcot
Slide 14: ANI Business Development Highlights
14 14 ANI Business Development Highlights Acquired undisclosed A NDA, March 2010 Acquired Reglan TM tablets, June 2011 Product development partnership with Ricon , June 2011 Acquired royalty arrangement with Teva , June 2013 Product development partnership with Sofgen , August 2013 Business Developm
Slide 15: Manufacturing Overview
15 15 Manufacturing Overview
Slide 16: ANI Manufacturing – Main Street Facility
16 16 ANI Manufacturing – Main Street Facility Location: Baudette , Minnesota ▪ 52,000 square feet of manufacturing , packaging, and warehouse facilities ▪ Rx solutions , suspensions , topicals , tablets , and capsules ▪ DEA - licensed for Schedule II controlled substances ▪ 17,000 square feet of la
Slide 17: ANI Manufacturing – IDC Road Facility
17 17 ANI Manufacturing – IDC Road Facility Location: Baudette, Minnesota ▪ Fully - contained h igh potency facility with capabilities to manufacture h ormone , steroid , and oncolytic products ▪ 47,000 square feet of manufacturing and packaging, and warehouse facilities ▪ 100 nano - gram per eight
Slide 18: ANI Summary
18 ANI Summary ANI is an emerging specialty/generic pharmaceutical firm with: ▪ Profitable base business generating organic growth ▪ Well capitalized balance sheet ▪ Experienced management team ANI is focused on: ▪ Internal product development ▪ Partnerships/strategic alliances ▪ Accretive acquisiti
ANI Pharmaceuticals — Investor Presentation (December 2013) on 6ix